Tarsus Pharmaceuticals, Inc.
TARS
Rangering i aksjer
#4540
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Aksjekurs
$70.72
Markedsverdi
$3.31B
Endring (1 dag)
0.31%
Endring (1 år)
2.94%
Land
US
Handel Tarsus Pharmaceuticals, Inc. (TARS)
Kategori
Healthcare
Aksjeprishistorikk for Tarsus Pharmaceuticals, Inc. (TARS)
Høyeste sluttskurs: $72.17 den 2026-10-01
Laveste sluttskurs: $21.51 den 2020-10-01
Laveste sluttskurs: $21.51 den 2020-10-01
Aksjeprishistorikk for Tarsus Pharmaceuticals, Inc. fra 2020 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -13.75% |
| 2025 | 54.26% |
| 2024 | 182.67% |
| 2023 | 21.69% |
| 2022 | -38.83% |
| 2021 | -32.39% |
| 2020 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $536.22 | 25.74% |
US
|
|
| $222.61 | 729.09% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $878.32 | 7.88% |
NL
|
